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Transcriptional profiling of differentially
vulnerable motor neurons at pre-symptomatic
stage in the Smn2b/- mouse model of spinal
muscular atrophy
Lyndsay M. Murray1,2,3,7*, Ariane Beauvais1, Sabrina Gibeault1, Natalie L. Courtney2,3 and Rashmi Kothary1,4,5,6
Abstract
Introduction: The term motor neuron disease encompasses a spectrum of disorders in which motor neurons are
the lost. Importantly, while some motor neurons are lost early in disease and others remain intact at disease
end-stage. This creates a valuable experimental paradigm to investigate the factors that regulate motor neuron
vulnerability. Spinal muscular atrophy is a childhood motor neuron disease caused by mutations or deletions in the
SMN1 gene. Here, we have performed transcriptional analysis on differentially vulnerable motor neurons from an
intermediate mouse model of Spinal muscular atrophy at a presymptomatic time point.
Results: We have characterised two differentially vulnerable populations, differing in the level neuromuscular
junction loss. Transcriptional analysis on motor neuron cell bodies revealed that reduced Smn levels correlate with
a reduction of transcripts associated with the ribosome, rRNA binding, ubiquitination and oxidative
phosphorylation. Furthermore, P53 pathway activation precedes neuromuscular junction loss, suggesting that
denervation may be a consequence, rather than a cause of motor neuron death in Spinal muscular atrophy. Finally,
increased vulnerability correlates with a decrease in the positive regulation of DNA repair.
Conclusions: This study identifies pathways related to the function of Smn and associated with differential motor
unit vulnerability, thus presenting a number of exciting targets for future therapeutic development.
Introduction
Motor neuron diseases (MNDs) are a heterogeneous group
of neurodegenerative disorders that are caused by a diverse
array of factors, including both genetic and sporadic. The
clinical severity can also vary widely, but MNDs are fre-
quently very severe, causing fatality within months to years of
diagnosis. Despite a range of causes and severities, motor
neuron diseases are united by the common vulnerability of
motor neurons. The reason why these cells are selectively
vulnerable to the genetic or environmental insult is unknown.
Importantly, however, not all motor neurons are equally af-
fected [26]. There are some pools of motor neuron in which
there are high levels of pathology throughout the motor unit,
and high levels of motor neuron loss [6, 22, 27, 16]. In other
pools in the same individual, there will be minimal evidence
of motor unit pathology, even at late stages of disease. The
reasons for this selective vulnerability are currently un-
known, however this phenomenon creates an exciting and
valuable opportunity to investigate the factors governing
motor neuron vulnerability and pathology. By comparing
different motor neuron groups we can investigate the mo-
lecular mechanisms underlying the disease, the molecular
mechanisms underlying motor neuron pathology and the
mechanisms that regulate motor neuron vulnerability.
Spinal muscular atrophy (SMA) is a childhood motor
neuron disease caused by mutations and deletions within
the survival motor neuron 1 gene (SMN1). There is a
second partially functional copy of the SMN gene, termed
SMN2. Due to a point mutation, SMN2 predominantly
produces a form of SMN that lacks exon 7, which is
* Correspondence: Lyndsay.Murray@ed.ac.uk
1Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa,
ON K1H 8 L6, Canada
2Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8
9XD, UK
Full list of author information is available at the end of the article
© 2015 Murray et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Murray et al. Acta Neuropathologica Communications  (2015) 3:55 
DOI 10.1186/s40478-015-0231-1
rapidly degraded. This gene therefore produces only low
levels of the full length SMN transcript. The copy number
of SMN2 can vary, making it an important phenotypic
modifier, with disease severity closely correlating to the
number of copies of the SMN2 gene. For this reason, SMA
has a range of clinical severities, which are classified into
types 0 to 4 based on age of onset and motor milestones
achieved. Despite a degree of controversy in the field as to
the cell types affected in SMA, it is clear that motor neu-
rons are particularly vulnerable to reduced SMN levels. In-
deed, SMA is typified by the loss of lower motor neurons
and the atrophy of associated skeletal musculature.
In SMA patients there is evidence of pathology at the
neuromuscular junction (NMJ) [37, 53]. Indeed in models
of SMA, structural pathology in the motor neuron is first
observed at the NMJ [40]. NMJs are lost early in the
disease, with denervation evident in some muscles prior to
symptom onset [40]. Additional defects at the NMJ include
neurofilament accumulation, poor terminal arborisation,
delayed post-synaptic maturation, defects in calcium hand-
ing and a disruption in synaptic vesicle release [10, 25, 28,
29, 34, 40, 44]. Importantly, not all NMJs are equally
affected. This has been well characterised in mouse models
of SMA, where there appears to be high levels of NMJ loss
in some muscles and very low levels of NMJ loss in others
[39, 40, 33]. This selective vulnerability has even been ob-
served within single muscles, where there are areas of high
levels of NMJ loss, and other areas showing no apparent
denervation [40]. The reasons for this differential vulner-
ability are unclear. One study has investigated the various
aspects of differentially vulnerable motor units, including
motor unit size, muscle fibre type, NMJ size, branching
patterns and Terminal Schwann cell number but found no
correlation with differential vulnerability [49]. There is
some evidence that differential vulnerability might correlate
with a differential sprouting competence, presenting the
possibility that relative plasticity can be an important modi-
fier. Furthermore, recent work has shown that there are de-
fects in synaptic remodelling at the NMJ in a mouse model
of SMA [39]. However, this has not been shown to be a de-
finitive modulator of vulnerability. The reasons for the vari-
ability in NMJ vulnerability are therefore currently unclear.
The reasons why motor neurons are selectively vulnerable
to a reduction in Smn are currently undefined and the cellu-
lar functions for Smn have long been debated. The best de-
scribed function for Smn is in pre-mRNA splicing [8, 57].
Growing evidence suggests that a reduction in Smn does not
result in widespread splicing defects however it has been
suggested that reduced Smn levels may cause splicing defects
in a small subset of RNAs [36, 3]. Other roles for Smn have
also been proposed, including transport of mRNAs [15] and
a potential role as a translational regulator [45]. Ultimately,
the precise cellular function of Smn that, when compro-
mised in SMA, causes motor neuron pathology is unknown.
SMA research has been greatly facilitated by a number of
mouse models [48]. These models are traditionally concen-
trated at the severe end of the spectrum, with a life expect-
ancy of less than 14 days of age [31, 38, 23]. Despite their
limitations, they have been instrumental in understanding
the pathophysiology of SMA and in therapeutic develop-
ment. The development of the Smn2B/- mouse model of
SMA has been an important addition to existing mouse
models [5, 20]. This mouse was created by introducing a
mutation in a splice enhancer site in the murine Smn
gene, resulting in production of 10-15 % of normal Smn
levels [20]. This mouse model displays all the hallmark
pathologies associated with SMA but, with a phenotypic
onset of around 10 days and a life span of around 28 days,
has a slightly milder phenotype than most other models
[5]. Importantly, unlike other mouse models, the Smn2B/-
mouse has a prolonged pre-symptomatic time period, thus
allowing analysis of the events preceding motor neuron
loss in SMA.
In this study, we have used the Smn2B/- mouse model of
SMA to investigate the transcriptional changes that occur
in differentially vulnerable motor neurons. We have iden-
tified and defined muscles with differential levels of NMJ
pathology and identified the time points associated with
the onset of degeneration. At the pre-degenerative time
points, we have used retrograde tracers to identify the
motor neuron cell bodies which correspond to these
differentially vulnerable NMJs and isolated them by laser
capture micro-dissection. Vulnerable and less vulnerable
motor neuron populations were isolated from both SMA
and wild-type control mice. We then performed RNAseq
on these differentially vulnerable motor neuron pools.
Comparative bioinformatics analysis and functional cluster-
ing was performed to identify the transcriptional changes
that correlate with reduced Smn levels, increased vulner-
ability and increased pathology. We demonstrate that
reduced Smn levels are correlative with a decrease in tran-
scripts implicated in ribosome, rRNA binding, ubiquitin
and oxidative phosphorylation. We demonstrate a selective
up regulation of cell death pathways in selectively vulner-
able motor neurons, and demonstrate that an increase in
these transcripts is observed prior to NMJ loss. Finally, we
demonstrate that there is a decrease in markers of DNA
repair in selectively vulnerable motor neurons. Overall this
work details a four way comparative analysis of differen-
tially vulnerable motor neurons using high resolution
transcriptional profiling.
Materials and methods
Mouse maintenance
The Smn2B/- mice [5] were established in our laboratory
and maintained in the University of Ottawa vivarium on a
C57BL/6 x CD1 hybrid background. Mice were sacrificed
by exposure to rising CO2 levels or by cervical dislocation.
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All procedures were performed in accordance with insti-
tutional guidelines (Animal Care and Veterinary Services,
University of Ottawa). Smn−/−;SMN2 mice [23] were
maintained in the animal facilities at the University of
Edinburgh and were sacrificed by overdose of anaesthetic.
Tissues were provided by generous agreement with Prof
Tom Gillingwater. All procedures were carried out in
accordance with the procedures approved and licenced by
the Home Office, United Kingdom.
Motor neuron labelling
Rhodamine conjugated dextran (RhDextran; 3000 MW;
Molecular Probes) was administered under general anaes-
thesia [17]. For immunostaining, a fixable analogue of the
RhDextran was used. Mothers were pre-dosed with bupre-
norphine prior to surgery. Mice were anesthetised by inhal-
ation of isofluorane (2 % in 1:1 N2O/O2). For abdominal
muscle labelling, a small incision between the last rib and
xyphoid process was made and 5 μl of 5 % RhDextran was
injected into the space between the external oblique muscle
and the transversus abdominis muscle. For cranial muscle
labelling, a small incision was made on the back of the
neck, and 5 μl of RhDextran was injected into the space
between the levator auris longus and auricularis superior
muscles. Mice were allowed to recover from anaesthetic
before being returned to standard cages. For muscle
analysis, mice we sacrificed 24 h later and muscles were
dissected, fixed in paraformaldehyde (PFA) and mounted
on slides. For spinal cords and brainstems, mice were sacri-
ficed 48 h later and spinal cords and brainstems were
removed and snap frozen in liquid nitrogen in 50 % Tissue
Tek O.C.T, 15 % sucrose in PBS.
Laser capture microdissection of RhDextran labelled
motor neurons
Spinal cords or brainstems were frozen and embedded as
described above. Tissues were then sectioned using a cryo-
stat at a thickness of 12 μm and mounted onto uncoated,
uncharged glass slides and immediately frozen at −20 °C
before being stored at −80 °C. Fluorescent motor neurons
were then identified and imaged on an inverted epifluores-
cent microscope. During this process, slides were kept
frozen using a freezing aerosol. Images were assembled
and montaged using Adobe Photoshop and printed onto
Fig. 1 Neuromuscular junction analysis reveals differential vulnerability between cranial and abdominal muscles. a Confocal micrographs show
neuromuscular junctions labelled with bungarotoxin (BTX, red) and antibodies against neurofilament and synaptic vesicle protein 2 (NF/SV2,
green). Images are P21 Smn2B/- muscles (Adductor auris longus [AAL]; Auricularis Superior [AS]; Levator Auris Longus caudal and rostral bands
[LALc, LALr]; External Oblique [EO]; Transversus Abdominis [TVA] and Rectus Abdominis [RA]. Control muscle is from P21 Smn2B/+ (control) TVA.
Note increase in denervated endplates and pre-synaptic swelling and poor pre-synaptic elaboration and endplate maturation in abdominal
(EO, TVA, RA) muscles compared to cranial (LAL, AS, AAL) and control muscles. Scale bar = 75 μm. b Bar chart (mean ± SEM) showing percentage
of fully occupied endplates in cranial and abdominal muscles in Smn2B/- mice at P21. ***P < 0.001, ** P < 0.01, *P < 0.05 by Kruskal-Wallis test with
Dunn’s Multiple Comparison Test in comparison to control (Smn2B/+ TVA)
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overhead transparencies. In the interim, slides were nissl
stained and dehydrated as follows: 75 % EtOH, 30 s;
ddH2O, 30 s; 1 % Toludine blue, 60 s; ddH2O, 30 s; 75 %
EtOH, 30 s; 95 % EtOH, 30 s; 100 % EtOH x 3, 60 s;
Xylene, 5 min; Air dry, 5 min. Steps were taken through-
out to minimise RNAse exposure and DEPC water was
used throughout.
LCM was performed using an Arcturus XT laser capture
microscope from Applied Biosystems. Labelled motor neu-
rons were identified by realigning the printed images of the
fluorescent motor neurons with the nissl stained motor
neurons on the LCM computer screen. This step was
necessary due to the water soluble nature of the RhDextran,
which is lost during LCM processing. Laser settings were
optimised for motor neuron cell body size. Captured cells
were snap frozen in qiazol (Qiagen) and stored at −80 °C
until extraction of RNA.
RNAseq
RNA was extracted using a Qiagen microRNA micro
RNeasy kit as per manufacturer’s instructions. RNA was
amplified using the ovation RNAseq system version 2 from
Nugen according to manufacturer instructions and tem-
plate DNA library construction was performed with the
Encore Rapid Library System (Nugen). Four cycles of PCR
were performed using reagents from the Ovation Ultralow
kit (Nugen). After that, 36 cycles of single-end sequencing
was performed with the Genome Analyzer IIx (Illumina).
Reads were mapped to the mouse mm9 assembly using
tophat (v1.4.0) using the transcripts from Ensembl release
67 to guide mapping. Quality control was performed using
RNAseQC and FastQC. Relative transcript levels were
compared using CuffDiff software v1.3 using the UCSC
transcript model. Significance was considered with a Q-
value of less that 0.05. The statistic package R was used to
Fig. 2 Time course analysis of abdominal NMJs reveals no denervation at pre-symptomatic stage (P10). a Confocal images show NMJs from P10
Smn2B/- abdominal muscles (External Oblique [EO]; Transversus Abdominis [TVA] and Rectus Abdominis [RA]) labeled with bungarotoxin (BTX, red)
and antibodies against neurofilament and synaptic vesicle protein 2 (NF/SV2, green). Control is from Smn2B/+ P10 EO muscle. Note that although
there is evidence of some pre-synaptic swelling, there is no evidence of denervation. P10 is therefore defined as a pre-degenerative time point.
Scale bar = 100 μm. b Scatter plot (mean ± SEM) shows the percentage of fully occupied endplates at P10, P13, P21 and P30 in individual TVA
(red), RA (orange) and EO (magenta) muscles. Note that no degeneration is observed at P10. Loss of NMJs is progressive from P13 onwards. N = 4
per time point per muscle
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identify transcriptional changes which were common in
more than one data set i.e. identifying transcriptional
changes occurring in SMAv and SMAr motor neurons
compared to their respective wild-types. Fold changes
were converted to log2. Therefore no change, which is
equivalent to a one fold change is equal to log21, which
equals 0. Therefore all numbers greater than 0 imply an
up-regulation. All numbers less that 0 imply a down-
regulation. As the biological consequences for a specific
magnitude of change are not known, we have not applied
any fold change restrictions to the data.
Functional clustering was performed using the functional
annotation clustering tool available on the Database for
Annotation, Visualization and Integrated Discovery (DA-
VID) online software from the National Institute of Allergy
and Infectious Diseases [13]. Using this tool, enrichment
analysis was performed using over 40 annotation categories.
An algorithm was then applied which clustered the func-
tional annotations based upon the degree of co-associated
genes. Only those functional annotations that had a signifi-
cant non-adjusted P value, were clustered. Those clusters
with an enrichment score of >1.3 are considered significant.
The enrichment score is a Log10 representation of the
non-adjusted P value. Therefore an enrichment score of 1.3
is reflective of a P value of 0.05. This software also provides
Kyoto Encyclopaedia of Genes and Genomes (KEGG) path-
way annotation to identify specific cellular pathways that
contain an enrichment for differentially expressed genes.
qPCR
For q-RT-PCR on laser captured motor neurons, motor
neuron cell bodies were isolated and RNA was extracted
and amplified as above and cDNA was diluted to approxi-
mately 100 ng/μl. Transcripts were selected for validation
Fig. 3 RhDextran can be used to label cell bodies corresponding to differentially vulnerable muscles. a Confocal images show motor neuron
cell bodies labeled with Neurofilament (NF, green) and DAPI (blue) following intramuscular injection of RhDextran (red). Note positive staining
in 2 of the 3 motor neurons present. Scale bar = 25 μm. b, c Montaged fluorescent micrographs show RhDextran labeling in the spinal cord
and brainstem following injection of RhDextran into the abdominal or cranial muscle groups, respectively. Scale bar = 300 μm (b), 500 μm (c).
d Bar chart (Mean ± SEM) showing number of labeled motor neurons in the spinal cord 48 h after abdominal muscle injection of 5 % RhDextran
into P8 control (wild-type) or Smn2B/- mice. N = 3 mice per genotype
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based on having a high relative expression (based upon the
read counts from the RNAseq results, preferably a read
value of >50) balanced with a large change in expression
level (ideally >1.5 fold). For whole spinal cord, RNA was
extracted using a micro RNeasy kit (Qiagen) and 1 ug of
RNA was used to perform reverse transcription using the
RT2 First Strand kit (Qiagen). SYBR gene based Q-RT-PCR
was performed using pre-optimised primers purchased
from BioRad. Amplification was performed using KAPA
SYBR fast universal PCR mastermix as per manufacturer
instructions on a BioRad CFX connect real-time PCR
detection system. Relative gene expression was calculated
using the 2-ΔΔcT formula [35]. β-actin and Y-Whaz were
used as reference genes.
Immuno-staining
For NMJ labelling, muscles were immediately dissected
from recently sacrificed mice and fixed in 4 % PFA (Elec-
tron Microscopy Science) in PBS for 15 min. Post-synaptic
AChRs were labelled with α-bungarotoxin (BTX) for
30 min. Muscles were permeabilised in 2 % Triton X-100
in PBS for 30 min, then blocked in 4 % bovine serum
albumin (BSA)/1 % Triton X-100 in PBS for 30 min before
incubation overnight in primary antibodies [Neurofilament
Fig. 4 RNAseq results show large number of differentially regulated transcripts. a Schematic diagram shows number of statistically significant
altered transcripts that were up or down regulated between the four experimental groups (WTr and SMAr, less vulnerable [cranial] motor neurons
from wild-type and Smn2B/- mice respectively; WTv and SMAv, vulnerable [abdominal/thoracic] motor neurons from wild-type and Smn2B/- mice
respectively). b-e Venn diagrams showing the number of common transcriptional changes between each of the primary comparisons which were
made in panel a. Diagrams show number of changes which went down (b) or up (c) in both SMAv and SMAr motor neurons compared to their
respective wild-types, and number of changes which went up (d) or down (e) in SMAv motor neurons compared to both SMAr and WTv
motor neurons
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(NF; 2H3) - Developmental Studies Hybridoma Bank;
synaptic vesicle protein 2 (SV2) - Developmental Studies
Hybridoma Bank; S100 – Dako; all 1:250] and visualised
with Cy3-conjugated secondary antibodies [Cy3 goat anti-
mouse; 1:250, Jackson]. Muscles were then whole-mounted
in Dako Fluorescent mounting media. Images were taken
with a Zeiss LSM-510 confocal microscope.
For spinal cord sections, spinal cords were removed from
recently sacrificed mice and fixed overnight in 4 % PFA.
Tissues were equilibrated in 30 % sucrose, embedded in
50 % Tissue Tek O.C.T, 15 % sucrose in PBS and sectioned
at 12 μm on a cryostat. Sections were washed in PBS,
permeabilised in 0.1 % Triton X-100 for 10 min and
blocked in 4 % BSA for 30 min before exposure to pri-
mary antibodies (rabbit anti-pH2AX, Cell Signalling
Technology; mouse anti-neurofilament heavy chain
[SMI-32] BioLegend) overnight. Secondary antibodies
(AlexaFluor 555 Goat anti-Rabbit, AlexaFluor 488
Rabbit anti-Mouse, both Life Technologies) were
applied for a period of 2–4 h at a dilution of 1:200.
Sections were counterstained in DAPI (Life Technologies)
and NeuroTrace® 500/525 (Life Technologies) as per
manufacturer instructions and mounted in mowoil®
(Sigma Aldrich). Sections were imaged on a Zeiss LSM-
510 confocal microscope. All laser settings were kept
constant between images.
Quantification and statistics
The percentage of fully occupied endplates was determined
by classifying each endplate in a given field of view either
fully occupied (pre-synaptic terminal (SV2 and NF) com-
pletely overlies endplate (BTX)), partially occupied (pre-
synaptic terminal only partially covers endplate (BTX)), or
vacant (no pre-synaptic label overlies endplate). At least 4
fields of view were analysed per muscle totalling >100
endplates per muscle.
For quantification of the number of labelled motor
neurons following RhDextran injection, longitudinal
sections of the anterior horn of the thoracic spinal
cord or pons and medulla of the brainstem were cut
and mounted sequentially on glass slides. The number
of fluorescent motor neurons that were visible was
counted per section. Quantification was done visually
using a Zeiss Axiovert 200 M microscope.
pH2AX quantification was done using Image-J software.
The average background intensity was subtracted from
each image, leaving only the pixels with an intensity above
background levels. The number of pH2AX foci per neuron
was then quantified. All quantification was done with the
experimenter blind to the experimental group.
Fig. 5 The majority of common transcriptional changes occur with the same directional regulation. a Scatter plots show correlation in fold
change in transcripts that were statistically significantly altered between both SMAv and SMAr motor neurons in comparison to their wild-type
equivalent. Note that most (222 of the 273) common changes identified shared the same directional regulation. b Scatter plots show correlation
in fold change in transcripts that were statistically significantly altered in SMAv motor neurons compared to both SMAr and WTv. Note that 274
of the 292 common changes identified shared the same directional regulation
Table 1 Statistically altered functional clusters of transcripts that
are differentially expressed in SMAv and SMAr compared to
their respective WTs
Down in SMA Up in SMA
Cluster Enrichment Cluster Enrichment
Ribosome/Translation 21.7 Repeat 2-2 2.4
Cytosolic Ribosome 4.7 RNA binding/
Splicesosome
2.2
rRNA binding 4.4 Heat-shock 1.7
Ubiquitin 2.1
Oxidative Phosphorylation 1.6
Listed clusters are generated from functional annotations which were significantly
enriched during functional annotation clustering. Significant enrichment was
considered to be those clusters with an enrichment score of >1.3
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All data was assembled and analysed using Microsoft
Excel and GraphPad Prism. All figures were assembled
using Adobe Photoshop.
Results and discussion
Differential motor unit vulnerability in the Smn2B/- mouse
model of SMA
Here we have used the Smn2B/- mouse to investigate the
transcriptional differences between differentially vulner-
able motor units in SMA. To do this, we first identified
two differentially vulnerable and experimentally accessible
pools of motor neurons. We aimed to identify one pool of
motor neurons in which we saw a high degree of NMJ
loss, and another pool of motor neurons in which there
was minimal or no evidence of NMJ loss at end stage of
disease. For this study, it was important to us to use mus-
cles that fulfilled the following criteria. Firstly, we aimed
to use thin and flat muscles, which are easy to perform
immunofluorescence on, thus allowing comprehensive
analysis of the whole muscle. This was important so we
could accurately quantify the level of morphological path-
ology present, and to ensure uniformity of pathology
throughout the muscle. Secondly, muscles had to be
experimentally accessible. This was important so tracer
injections could be performed to specifically target the
muscle group of interest with minimal trauma or risk of
injection side effects, which may occur in the diaphragm
or intercostal for example. Lastly, we felt it was preferable
to use local groups of muscles, rather than single muscles.
Clearly there is significant molecular variability between
muscles. By using muscle groups, we minimised the contri-
bution of inter-muscular variability. After investigating
NMJ pathology in a range of muscles situated throughout
the body, we defined our vulnerable group as those motor
neurons innervating a group of abdominal muscles, specif-
ically transversus abdominis (TVA), rectus abdominis (RA)
and external oblique (EO). Collectively 20.5 % of NMJs
were denervated by P21 in these muscles, and all these
muscles display significant NMJ defects (Fig. 1). We
observed defects such as neurofilament accumulation and
poor terminal arborisation. Endplates appeared immature
and there was a high number of vacant denervated end-
plates. Importantly, pathology was uniform throughout
each muscle (data not shown). For our less vulnerable
group of motor neuron, we chose to use motor neurons
innervating a group of cranial muscles, encompassing
levator auris longus (LAL), auricularis superior (AS) and
adductor auris longus (AAL). Collectively, 97.9 % of NMJs
Fig. 6 Down-regulation of transcripts involved in the ribosome and rRNA binding. a Gene list show transcripts associated with the ribosome or
rRNA binding which were statistically altered in SMAv and SMAr motor neurons compared to their respective wildtypes. No annotation implies
just associated with the ribosome; *rRNA binding proteins and ribosome; ♯rRNA binding proteins not implicated in the ribosome. Arrow indicates
transcripts that were investigated by qPCR. b Bar charts (Mean ± SEM) showing relative expression of RPL7, RPLP1, RPS27a, MRPL20 and LSM5 in
WTv and SMAv motor neurons. N = 4 biological replicates, each approximately 200 motor neurons from 2–3 mice. Note that all qPCR results
confirmed RNAseq results with the exception of LSM5 for which there was no change. ***P < 0.001, **P < 0.01 by Mann Whitney U test
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were fully occupied at P21 in these muscles (Fig. 1b). Pre-
synaptic terminals appeared more elaborate compared to
those in abdominal muscles, and endplates displayed more
complexity consistent with a more mature phenotype.
Again, pathology was generally consistent throughout each
muscle. One exception to this was a slight increase in NMJ
pathology in the rostral band of the LAL muscle compared
to the caudal band, where we observed 95.6 % of dener-
vated endplates compared to 98.3 % in the LALc. Intri-
guingly, this is actually the opposite to what is observed in
more severe mouse models of SMA [40]. Importantly,
however, this denervation was still comparatively mild
compared to abdominal muscles.
It is important to note that our goal was to investigate
the transcriptional differences between differentially vulner-
able motor neurons prior to the onset of degeneration. We
therefore aimed to identify a time point just prior to the
onset of NMJ loss in vulnerable muscles. We performed a
time course analysis of NMJ loss in the TVA, RA, IO and
EO muscles. This revealed that the latest time point at
which there was no evidence of NMJ loss was P10 (Fig. 2).
Analysis of NMJs at P10 revealed no denervation in
any of the abdominal muscles analysed (Fig. 2a). We
have therefore defined this as a pre-degenerative time
point and aimed to use this time point for all subse-
quent transcriptional analysis.
Motor unit tracing
To identify the motor neuron cell bodies that correspond
to the differentially vulnerable pools of NMJs, we used
rhodamine-conjugated dextran as a retrograde tracer. For
abdominal muscle, RhDextran was injected into the space
between the TVA and RA/EO muscles. For cranial muscles,
RhDextran was injected into the space between the LAL
and AS/AAL muscles. For initial experiments, mice were
sacrificed 24 h later and muscles were analysed for the
presence of RhDextran. Analysis of abdominal muscles
revealed strong staining in the superior parts of the EO,
RA and TVA (data not shown). Importantly, the dye
remained relatively local to the site of injection, and did
not leach to surrounding intrinsic back or appendicular
muscles. Equivalent analysis was performed in the cranial
muscles. Strong staining was observed in the LAL, AS and
AAL muscles and again dye was observed to remain local
to the site of injection, with minimal leakage to surround-
ing muscles or to the contralateral side. This analysis
confirmed that we were labeling the targeted muscles
specifically and robustly.
For subsequent experiments, mice were sacrificed 48 h
following RhDextran injection and spinal cords and brain-
stems were analysed for the presence of RhDextran stain-
ing. This revealed a discrete cluster of motor neurons in
the thoracic spinal cord, which correspond to the motor
neurons innervating the abdominal muscles, and a cluster
of labeled motor neurons in the facial nucleus of the brain-
stem, corresponding to those motor neurons innervating
the cranial muscles (Fig. 3). Quantification of the number
of labeled motor neurons between Smn2B/- mice and wild-
type control animals revealed no difference between groups
(Fig. 3d). This suggests that labeling efficiency is not com-
promised in Smn2B/- mice. This was important to consider
given previous work reporting defects in axon transport in
SMA mouse models [11].
Transcriptional analysis of differentially vulnerable motor
neurons
Following identification of suitable differentially vulnerable
motor neuron populations, and validation of the RhDextran
labeling methodology, laser capture micro-dissection
(LCM) was used to isolate the cell bodies corresponding to
these neurons. The motor neuron cell bodies were isolated
from Smn2B/- and wild-type mice, with approximately 250
motor neurons from 2–3 mice per biological replicate.
This resulted in four experimental groups. Vulnerable (ab-
dominal) motor neurons from Smn2B/- and wild-type mice
(SMAv and WTv respectively) and less vulnerable (cranial)
motor neurons from Smn2B/- and wild-type mice (SMAr
and WTr), respectively. Transcriptional analysis was
performed using RNAseq and expression profiles were
Fig. 7 Down-regulation of transcripts involved in Ubiquitination.
a Gene list show transcripts associated with ubiquitin which were
statistically significantly altered in SMAv and SMAr motor neurons
compared to their respective wildtypes. Arrow indicates transcript
that was investigated by qPCR. b Bar chart (Mean ± SEM) showing
relative expression of Ubiquitin (Ubb) in WTv and SMAv motor
neurons. N = 4 biological replicates, each approximately 200 motor
neurons from 2–3 mice. Note that qPCR results confirmed
down-regulation of Ubb. ***P < 0.001 by Mann Whitney U test
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compared between each experimental group (Additional
file 1). For each comparison, around 17,500 genes were
identified and compared. From this number, there were
around 1200 to 1500 transcriptional changes between
each of our four comparative groups (Fig. 4). Encour-
agingly, preliminary analysis of the data revealed a number
of changes that have been previously implicated in path-
ology in SMA or in motor neuron vulnerability. For
example, we observed a significant 4.8 Log2 fold up regu-
lation of cyclin dependant kinase inhibitor 1A (CDKN1a)
between SMAv and WTv motor neurons, and a 2.8 Log2
fold up regulation of CDKN1a between SMAr and WTr
motor neurons. Interestingly, a significant up-regulation
of CDKN1a has been reported in numerous other models
of SMA, including in other mouse models of SMA [60]
and embryonic stem cell derived motor neurons from
SMA mouse models [58]. We revealed a significant 1.3
Log2 fold down-regulation of chondrolectin (Chodl),
which has previously been described in other mouse
models of SMA [3, 60]. There was a significant 1.03 fold
Log2 up-regulation of the Fused in Sarcoma transcript
(Fus), which has been implicated in motor neuron path-
ology in amyotrophic lateral sclerosis (ALS), and the
protein has been shown to interact with Smn [18, 59]. We
also observed a significant 3.5 Log2 fold down regulation
of insulin like growth factor 1 (IGF1) which has previously
been reported in serum and liver of a SMA mouse model
[24]. Interestingly, we did not observe any change in Fus,
Fig. 8 Down-regulation of transcripts involved in oxidative phosphorylation. a Gene list show transcripts associated with oxidative phosphorylation
which were statistically altered in SMAv and SMAr motor neurons compared to their respective wildtypes. Arrow indicates transcript that was
investigated by qPCR. b, c Bar charts (Mean ± SEM) showing relative expression of haemoglobin beta chain (Hbb-b1) in WTv and SMAv motor
neurons (b) and in WTv compared to WTr motor neurons. Note that qPCR results confirmed down-regulation of Hbb-b1 in SMAv motor neurons
and also revealed an increase in Hbb-b1 levels in less vulnerable (WTr) motor neurons compared to vulnerable motor neuron (WTv). N = 4 biological
replicates, each approximately 200 motor neurons from 2–3 mice. *P < 0.05 by Mann Whitney U test
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IGF1 or Chodl in SMAr motor neurons compared to
WTr. As these genes have also been implicated in motor
neuron pathology in amyotrophic lateral sclerosis [9, 30,
52, 56], this perhaps indicates that these genes are
involved in motor neuron pathology, which occurs as a
secondary effect to the loss of Smn protein. These genes
are therefore potential common downstream regulators of
neuronal pathology in a variety of different motor neuron
diseases.
What transcriptional changes occur in motor neurons
when Smn is absent: transcriptional differences in
vulnerable motor neurons between SMA and WT mice
We first aimed to use this data to investigate the cellular
processes disrupted when Smn levels are decreased. We
reasoned that Smn levels are reduced in both SMAv and
SMAr motor neurons compared to their respective wild-
type counterparts. We therefore looked for the transcrip-
tional changes that occurred in both of these populations.
In SMAr motor neurons, there were 1557 transcripts,
which were statistically up or down regulated compared
to WTr motor neurons. In SMAv motor neurons, there
were 1277 transcripts, which were statistically up or down
regulated compared to WTv motor neurons. Of these
changes, 273 were found in both comparisons and the
majority (222) showed a common directional change, with
121 being up-regulated and 101 being down regulated
(Fig. 4, Fig. 5a, Additional file 2).
Functional clustering of these transcripts was performed
using DAVID bioinformatics resources version 6.7. This
revealed a number of significantly altered functional clus-
ters (Table 1). As we were looking for transcripts impli-
cated in the function of Smn, we decided to focus on
transcripts that are down-regulated in SMAv and SMAr
motor neurons. The most significant clusters which were
down-regulated comprised of transcripts involved in the
ribosome and cytosolic ribosome. This was closely
followed by transcripts implicated in rRNA binding. In-
deed there was considerable overlap between these three
functional clusters, with the majority of rRNA binding
proteins also implicated in the ribosome (Fig. 6). In order
to confirm this down regulation of transcripts involved in
rRNA binding and ribosome, we performed qPCR valid-
ation on new biological replicates of cDNA samples
prepared from motor neurons isolated as described above,
and compared transcript levels between SMAv and WTv
samples. This confirmed a down-regulation of RPL7,
RPLP1, RPS27a and MRPL20 (Fig. 6b). The only transcript
that did not validate was LSM5.
The data presented above therefore indicated that
there is a down regulation of factors involved in the
ribosome, particularly in those involved in rRNA bind-
ing. Smn has long been established as an RNA binding
protein, with work generally focused on its role as an
mRNA binding protein, and its role on pre-mRNA spli-
cing and mRNA transport. Less is known about its
potential role in rRNA metabolism. It is easy to specu-
late that reduced Smn levels may disrupt the production
or assembly for rRNA and lead to downstream defects
in ribosomal function. Furthermore, Smn has recently
been identified as a negative regulator of translation
[45]. Smn has also been shown to localise to the nucle-
olus and interact with non-ribosomal nucleolar proteins,
suggesting that it has a role in ribonucleoprotein com-
plex assembly [32, 54]. Interestingly, recent work has
identified that mutations in genes involved in ribo-
some subunit assembly and maturation lead to motor
neuron specific defects in Spinal Muscular Atrophy
with Respiratory Distress (SMARD) [7, 12, 19]. This
work therefore creates an intriguing parallel between
SMA and SMARD and warrants further work into
ribosome assembly and function in Smn depleted
motor neurons.
The functional clustering also revealed a down regu-
lation of transcripts involved in ubiquitin metabolism
(Table 1, Fig. 7). The down regulation of ubiquitin
(Ubb) was confirmed by qPCR (Fig. 7b). A disruption
in ubiquitin homeostasis has recently been reported in
SMA mouse models. Specifically, the authors observed
a disruption in proteins implicated in ubiquitination
in proteomic analysis on synapses from P1 SMA mice
and a marked reduction in ubiquitin activating enzyme
1 (UBA1) levels in spinal cord and muscle from SMA
mice [55]. They suggest this down-regulation in UBA1
Table 2 Statistically altered functional clusters of transcripts that
are differentially expressed in SMAv vs. WTv
Down in SMAv Up in SMAv
Cluster Enrichment Cluster Enrichment
Ribsome 10.7 Metal Ion Binding 3.2
Mitochondrial
Membrane
2.7 Nucleoplasm 3.2
Ubl Conjugation 2.3 RNA binding 2.6
Mitochondria 2.14 Transcriptional
Regulation
2.5
Bone Development 1.6 Cytoskeleton 2.1
Mitochondrial
Ribosome
1.55 mRNA processing 2.1
Focal Adhesion 1.52 Nuclear Speck 1.6
Mitochondrial
Respiratory Chain
1.39 Chromatin
Regulator
1.6
Transcriptional
Activator
1.6
Cell death 1.3
Listed clusters are generated from functional annotations which were significantly
enriched during functional annotation clustering. Significant enrichment was
considered to be those clusters with an enrichment score of >1.3
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leads to an increase in beta-catenin levels, and inhib-
ition of beta-catenin signalling rescued motor neuron
specific defects in zebrafish and mouse models of
SMA. This work therefore confirms the disruption of
this pathway and promotes further work to dissect the
mechanism by which a reduction in Smn levels lead to
a disruption in ubiquitin homeostasis.
We also observed enrichment for transcripts involved
in oxidative phosphorylation (Table 1, Fig. 8). Encour-
agingly, oxidative phosphorylation was also the top hit
on a proteomic screen on synapses from a P1 SMA
mouse model [55]. Of particular note, we reveal a down
regulation of haemoglobin beta 1 (Hbb-b1) which was
confirmed by qPCR between SMAv and WTv motor
Fig. 9 Selective up-regulation of transcripts involved in cell death in vulnerable motor neurons. a Gene list show transcripts associated with cell death
which were statistically significantly altered in SMAv compared to WTv motor neurons. Arrow indicates transcripts that were investigated by qPCR. b Bar
charts (Mean ± SEM) showing relative expression of PMAIP and CDKN1a in WTv, SMAv, WTr and SMAr motor neurons. Note that qPCR results confirmed
up-regulation of PMAIP and CDKN1a in SMAv motor neurons compared to WTv. There was also a significant up-regulation of CDKN1a in SMAr motor
neurons. N= 4 biological replicates, each approximately 200 motor neurons from 2–3 mice. c Bar charts (Mean ± SEM) showing relative expression of
PMAIP, Fas and CDKN1a in whole spinal cord from Smn2B/- and Smn−/−;SMN2 mice compared to wild-type or Smn+/+;SMN2 (control) respectively. This
showed an up-regulation of all transcripts in SMA mouse models, with the exception of CDKN1a in Smn−/−;SMN2 samples. Note that this demonstrates
the up-regulation of transcripts associated with cell death pathways can be seen at pre-symptomatic time points in two different mouse models of SMA.
***P< 0.001, *P< 0.05 by Mann Whitney U test
Murray et al. Acta Neuropathologica Communications  (2015) 3:55 Page 12 of 17
neurons (Fig. 8b). Interestingly, we also noted a strong
increase in Hbb-b1 levels in WTr motor neurons com-
pared to WTv. This suggests that Hbb levels may be
higher in less vulnerable motor neurons. This makes
haemoglobin an exciting candidate as a regulator of motor
neuron vulnerability. Indeed, recent work has demon-
strated that haemoglobin subunits are expressed in neu-
rons in both rats and humans [41, 43] and colocalised
with the mitochondria inner membrane [47]. They have
been observed to be up-regulated in response to ischemic-
reperfusion injury in rats and in an in vitro ischemic injury
model in primary cortical neuron cultures [21]. Further-
more, haemoglobin chains have been shown to be down-
regulated in a rat model of chronic stress [1], in microglia,
astrocytes and brain mitochondria from aged mice [42,
47]. The role of haemoglobin in neurons is unclear, al-
though it been suggested to act as an oxygen carrier or to
be protective against oxidative stress [2, 46]. We may
speculate about the relationship between Smn and haemo-
globin, however it is perhaps more likely that the down-
regulation of Hbb transcripts that we observed is a
downstream consequence of the cellular defects caused by
a reduction in Smn levels. However, as outlined above,
there is strong evidence that haemoglobin can influence
pathways implicated in neuronal vulnerability, and this
makes it an exciting candidate for further investigation.
Up-regulation of transcripts involved in programmed cell
death in selectively vulnerable motor neurons that
precedes NMJ pathology
Functional clustering of the transcriptional changes occur-
ring between SMAv and WTv motor neurons revealed a
number of clusters, most of which were common with the
functional clustering of changes between SMAr and WTr
motor neurons (Table 2). One functional cluster that was
only observed in SMAv vs. WTv motor neurons, was an
up-regulation of factors involved in cell death (Fig. 9). This
functional cluster was not significantly altered in equiva-
lent analysis on SMAr vs. WTr motor neurons. There
were 13 transcripts that are associated with cell death
pathways, which were up-regulated in SMAv motor
neurons compared to SMAr (Fig. 9a). Of these, only 2
were statistically up-regulated in SMAr motor neuron
compared to WTr (Fig. 9a). Of particular note, 5 of these
transcripts were up-regulated in SMAv motor neurons
compared to SMAr (Fig. 9a). KEGG pathway analysis
revealed that a number of these up-regulated transcripts
pertain to the P53 signalling pathway. Specifically, the
RNAseq results indicated a 4.8 Log2 fold and 5.9 Log2 fold
up-regulation of PMAIP and CDKN1a respectively. This
up-regulation was confirmed by qPCR on cDNA from
laser captured motor neurons. An up-regulation of Fas,
PMAIP and CDKN1a was also seen in cDNA deriving
from whole spinal cord from P10 Smn2B/- mice (Fig. 9c).
A similar up-regulation was observed in spinal cord from
pre-symptomatic (P2) Smn−/−;SMN2 mice, a more severe
mouse model of SMA (Fig. 9c).
The up-regulation of factors that are strongly impli-
cated in apoptotic pathways may at first glance appear
unsurprising. However, we must remember that this
up-regulation is occurring in two different mouse
models of SMA at a pre-degenerative time point, prior
to any NMJ loss. This suggests that cell death pathways
are activated at the cell body prior to pathology at the
NMJ. A central debate in the SMA research field has
been whether SMA is due to a loss of a central house-
keeping function for Smn, or whether it is due to a loss
of a specific axonal or synaptic role for Smn [8, 15].
The observation that NMJs are lost so early in the dis-
ease has often been used as evidence for the latter. The
Table 3 Statistically altered functional clusters of transcripts that
are differentially expressed in SMAv compared to WTv and
SMAr
Down in SMAv Up in SMAv
Cluster Enrichment Cluster Enrichment
Metal Ion Binding 3.07 Mitochondrial inner
membrane
1.38
Positive regulation of
transcription
2.52
Membrane 1.73
Chromatin/methylation 1.47
Positive regulation of
DNA repair
1.38
Nucleotide Binding 1.35
Listed clusters are generated from functional annotations which were significantly
enriched during functional annotation clustering. Significant enrichment was
considered to be those clusters with an enrichment score of >1.3
Table 4 Genes implicated in DNA repair that were down
regulated in SMAv motor neurons compared to both SMAr and
WTv
Gene symbol Log2 fold change
SMAv vs. WTv SMAv vs. SMAr
EYA1 −3.0 −3.1
C230052I12RIK −2.2 −1.7
SREBF1 −1.8 −1.9
CHD3 −1.5 −1.8
FTSJD2 −1.2 −1.1
CHD8 −1.2 −1.1
KDM1B −1.2 −1.6
BRE −1.1 −1.2
HBB-B1 −1.1 −1.7
MLH3 −1.0 −1.3
MLL5 −0.9 −1.1
ARPP21 −0.6 −1.8
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data presented here suggests that cell death pathways
are activated before degenerative events can be ob-
served at the axon or NMJ. Clearly, this work does not
eliminate a role for Smn in the axon or synapse. It also
remains possible that defects in this synaptic or axonal
role leads to cell death activation at the cell body,
which is followed by the withdrawal of synaptic and
axonal compartments. However, it is intriguing to draw
parallels to congenic myasthenia syndromes, which are
caused by specific synaptic defects [14]. In these condi-
tions there is profound synaptic dysfunction and de-
nervation, however this does not lead to activation of
cell death pathways and motor neuron cell body loss.
Further work is clearly required to determine the time
course and specific location of motor unit pathology in
SMA and investigate whether synaptic defects in SMA
are a cause or consequence of cell death pathway acti-
vation at the cell body.
What transcriptional changes correlate with motor
neuron vulnerability: Transcriptional differences
selectively occurring in vulnerable motor neurons
In this study we were particularly keen to identify regula-
tors of motor neuron vulnerability. For this analysis, we
reasoned that any changes that occurred only in SMAv
motor neurons compared to either WTv motor neurons,
or to SMAr motor neurons, could be specifically impli-
cated in NMJ and motor unit pathology. We therefore
looked for transcriptional changes that occurred in SMAv
motor neurons compared to SMAr and compared to
WTv. By comparing SMAv and SMAr motor neurons, we
identified 1299 transcripts that were up or down-regulated
(Fig. 4). As highlighted above, when comparing SMAv and
WTv motor neurons, we identified 1277 transcripts that
were up or down-regulated (Fig. 4). Of the changes that
were identified in these two comparisons, 292 were com-
mon, and notably 94 % occurred with the same directional
Fig. 10 Increase in markers of DNA repair complexes correlate with decreased vulnerability. a Confocal images show motor neurons from WTr,
WTv, SMAr and SMAv motor neuron labeled with RhDextran (red), DAPI (blue) and antibodies against phosphorylated version of H2A histone
family member X (pH2AX, green), which is a marker of DNA repair complexes. Note that the highest levels of pH2AX staining were observed in
WTr motor neurons. Scale bar = 50 μm. b Scatter plot quantification of the number of pH2AX positive foci per motor neuron in WTr, WTv, SMAr
and SMAv motor neurons. There was a decrease in staining in WTv motor neurons, which suggests decreased DNA repair complexes correlate
with increased vulnerability. There was also a decrease in DNA repair complexes in both SMAv and SMAr motor neurons. N = 4 spinal cord and
25/21/48/27 motor neurons per group, *** P <0.001 WTr compared to WTv, SMAr and SMAv
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regulation (Fig. 5b). Indeed we found 140 and 134 tran-
scriptional changes which were up or down regulated
respectively in SMAv motor neurons compared to both
WTv and SMAr (Additional file 3). Of particular note, both
IGF1 and IGF2 were significantly down-regulated in SMAv
motor neurons. IGF1 has previously been reported to be
down-regulated in SMA models, and increasing IGF1 levels
have been shown to be phenotypically beneficial [4, 50, 51].
IGF2 levels have been associated with differential neuronal
vulnerability in an ALS model, down-regulated in an ex-
perimental model of stress, and suggested to have neuro-
protective qualities against excitotoxicity [1, 22]. RNAseq
results also implied that PMAIP and CDKN1a were select-
ively up-regulated in SMAv motor neurons. For PMAIP,
this result was confirmed by qPCR (Fig. 9).
Functional clustering of these changes highlighted a num-
ber of cellular pathways, which are detailed in Table 3. Due
to their enrichment selectively in vulnerable motor neu-
rons, these clusters are all potentially of interest and worthy
of further investigation. We were particularly interested to
note the decrease in factors involved in the positive regula-
tion of DNA repair. The transcripts within this functional
cluster are listed in Table 4. This presents the possibility
that the response to DNA damage is decreased in select-
ively vulnerable motor neurons. In order to investigate this
further, we looked at phospho-histone H2AX (pH2AX)
levels in differentially vulnerable motor neurons (Fig. 10).
pH2AX is one of the first proteins to be recruited to sites of
DNA damage, and recruits other proteins involved in DNA
repair to form a DNA repair complex. Immunohistochemi-
cal staining of differentially vulnerable motor neurons with
antibodies against pH2AX revealed a marked increase in
foci number in WTr motor neurons compared to WTv.
This suggests that there is a basal increase in the level of
DNA repair occurring in less vulnerable motor neurons.
The number of pH2AX foci was reduced in both SMAv
and SMAr motor neurons compared to WTr, suggesting a
further decrease in the levels of DNA repair in Smn2B/-
motor neurons. Interestingly, there remained a trend for in-
creased DNA repair in SMAr motor neurons compared to
SMAv. This data indicated that the number of DNA repair
complexes correlates with relative vulnerability.
The data presented above provide preliminary evidence
that an increase in DNA repair can be neuroprotective. It is
unclear whether this is because there is a greater
requirement for DNA repair in less vulnerable motor
neurons, or whether the requirement is similar in both cell
populations, but DNA repair is just more efficient in less
vulnerable cells. The DNA damage repair system is a crucial
system to maintain genomic integrity, which is especially
relevant for terminally differentiated and long-lived cells
such as neurons. It is easy to speculate how an increase in
the activity in the basic cellular repair mechanisms could
be neuroprotective. Indeed, DNA damage can be a key
mechanism by which apoptosis is induced. The increase in
DNA repair in less vulnerable motor neurons may reduce
the likelihood of apoptotic activation. A number of hypoth-
eses state that stressed cells cope better with additional
stress. It is possible that this basal higher level of cellular
stress primes selective motor neuron populations to cope
better with the additional stresses when Smn levels are re-
duced. Clearly this idea requires further validation in this
context, however this has important implications both for
development of neuroprotective strategies, and for under-
standing the mechanisms by which sub-populations of neu-
rons are rendered more vulnerable to a variety of insults.
Conclusions
In summary, the data presented above represent detailed
transcriptional analysis on differentially vulnerable motor
neurons from an SMA mouse model at a pre-symptomatic
time point. They highlight a number of pathways which are
disrupted upon Smn depletion, including a reduction of
transcripts involved with the ribosome, rRNA binding,
ubiquitination and oxidative phosphorylation. Subsequent
work is required to ascertain the mechanisms by which
reduced Smn levels impact upon these pathways. We have
also revealed an early and selective up-regulation of cell
death pathways, and it will now be key to understand how
cell death pathway activation relates to the time course of
pathology within the motor unit. Finally, we show that,
among a number of pathways of potential interest, an
increase in DNA damage repair complexes correlate with a
reduced vulnerability. Future efforts dissecting the mechan-
ism of this protection are now warranted.
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